Porphyrin photosensitizer molecules as effective medicine candidates for photodynamic therapy: electronic structure information aided design
- PMID: 39285886
- PMCID: PMC11404311
- DOI: 10.1039/d4ra05585c
Porphyrin photosensitizer molecules as effective medicine candidates for photodynamic therapy: electronic structure information aided design
Abstract
Traditional photosensitizers (PS) in photodynamic therapy (PDT) have restricted tissue penetrability of light and a lack of selectivity for tumor cells, which diminishes the efficiency of PDT. Our aim is to effectively screen porphyrin-based PS medication through computational simulations of large-scale design and screening of PDT candidates via a precise description of the state of the light-stimulated PS molecule. Perylene-diimide (PDI) shows an absorption band in the near-infrared region (NIR) and a great photostability. Meanwhile, the insertion of metal can enhance tumor targeting. Therefore, on the basis of the original porphyrin PS segments, a series of metalloporphyrin combined with PDI and additional allosteric Zn-porphyrin-PDI systems were designed and investigated. Geometrical structures, frontier molecular orbitals, ultraviolet-visible (UV-vis) absorption spectra, adiabatic electron affinities (AEA), especially the triplet excited states and spin-orbit coupling matrix elements (SOCME) of these expanded D-A porphyrin were studied in detail using the density functional theory (DFT) and time-dependent density functional theory (TDDFT) methods. PS candidates, conforming type I or II mechanism for PDT, have been researched carefully by molecular docking which targeted Factor-related apoptosis (Fas)/Fas ligand (Fasl) mediated signaling pathway. It was found that porphyrin-PDI, Fe2-porphyrin-PDI, Zn-porphyrin-PDI, Mg-porphyrin-PDI, Zn-porphyrin combined with PDI through single bond (compound 1), and two acetylenic bonds (compound 2) in this work would be proposed as potential PS candidates for PDT process. This study was expected to provide PS candidates for the development of novel medicines in PDT.
This journal is © The Royal Society of Chemistry.
Conflict of interest statement
There are no conflicts to declare.
Figures
References
-
- Zaimy M. A. Saffarzadeh N. Mohammadi A. Pourghadamyari H. Izadi P. Sarli A. Moghaddam L. K. Paschepari S. R. Azizi H. Torkamandi S. Tavakkoly-Bazzaz J. New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles Cancer Gene Therapy. Cancer Gene Ther. 2017;24:233. - PubMed
-
- Pham T. C. Nguyen V. N. Choi Y. Lee S. Yoon J. Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy. Chem. Rev. 2021;121:13454–13619. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials